Pancreatic cancer

Shigeu Yamada, Kohtaro Terashima, Makoto Shinoto, Shigeo Yasuda, Miho Shiomi, Tetsuro Isozaki

Research output: Chapter in Book/Report/Conference proceedingChapter

3 Citations (Scopus)

Abstract

Pancreatic cancer is the fifth leading cause of cancer death and is considered to be one of the most lethal cancers in Japan.Complete surgical resection is the only curative treatment. Even if curative resection is performed, the disease usually recurs, and 5-year survival rates are less than 20%. Chemotherapy or chemoradiotherapy is selected as a standard treatment for unresectable pancreatic cancer. However, since pancreatic cancer is often resistant to chemotherapy and radiotherapy, the local control and survival rates are very low. We conducted a phase I/II clinical trial using carbon ion radiotherapy (C-ion RT) for patients with operable and locally advanced pancreatic cancer. This was delivered preop- eratively in 8 fractions over 2 weeks, was well tolerated, and resulted in excellent local control and survival rates. C-ion RT for patients with locally advanced pancreatic cancer was also well tolerated, even when concomitantly administered with the highest dose of gemcitabine (1,000 mg/m2), and likewise resulted in a good survival rate. In this chapter, we discuss current treatment methods and the results of C-ion RT for pancreatic cancer at the National Institute of Radiological Sciences.

Original languageEnglish
Title of host publicationCarbon-Ion Radiotherapy
Subtitle of host publicationPrinciples, Practices, and Treatment Planning
PublisherSpringer Japan
Pages221-228
Number of pages8
ISBN (Electronic)9784431544579
ISBN (Print)9784431544562
DOIs
Publication statusPublished - Jan 1 2014

Fingerprint

Pancreatic Neoplasms
Heavy Ion Radiotherapy
Survival Rate
gemcitabine
Drug Therapy
Phase II Clinical Trials
Clinical Trials, Phase I
Chemoradiotherapy
Cause of Death
Neoplasms
Japan
Radiotherapy
Therapeutics

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Yamada, S., Terashima, K., Shinoto, M., Yasuda, S., Shiomi, M., & Isozaki, T. (2014). Pancreatic cancer. In Carbon-Ion Radiotherapy: Principles, Practices, and Treatment Planning (pp. 221-228). Springer Japan. https://doi.org/10.1007/978-4-431-54457-9_26

Pancreatic cancer. / Yamada, Shigeu; Terashima, Kohtaro; Shinoto, Makoto; Yasuda, Shigeo; Shiomi, Miho; Isozaki, Tetsuro.

Carbon-Ion Radiotherapy: Principles, Practices, and Treatment Planning. Springer Japan, 2014. p. 221-228.

Research output: Chapter in Book/Report/Conference proceedingChapter

Yamada, S, Terashima, K, Shinoto, M, Yasuda, S, Shiomi, M & Isozaki, T 2014, Pancreatic cancer. in Carbon-Ion Radiotherapy: Principles, Practices, and Treatment Planning. Springer Japan, pp. 221-228. https://doi.org/10.1007/978-4-431-54457-9_26
Yamada S, Terashima K, Shinoto M, Yasuda S, Shiomi M, Isozaki T. Pancreatic cancer. In Carbon-Ion Radiotherapy: Principles, Practices, and Treatment Planning. Springer Japan. 2014. p. 221-228 https://doi.org/10.1007/978-4-431-54457-9_26
Yamada, Shigeu ; Terashima, Kohtaro ; Shinoto, Makoto ; Yasuda, Shigeo ; Shiomi, Miho ; Isozaki, Tetsuro. / Pancreatic cancer. Carbon-Ion Radiotherapy: Principles, Practices, and Treatment Planning. Springer Japan, 2014. pp. 221-228
@inbook{b4b22785cbe145e9b3187e6525297c2d,
title = "Pancreatic cancer",
abstract = "Pancreatic cancer is the fifth leading cause of cancer death and is considered to be one of the most lethal cancers in Japan.Complete surgical resection is the only curative treatment. Even if curative resection is performed, the disease usually recurs, and 5-year survival rates are less than 20{\%}. Chemotherapy or chemoradiotherapy is selected as a standard treatment for unresectable pancreatic cancer. However, since pancreatic cancer is often resistant to chemotherapy and radiotherapy, the local control and survival rates are very low. We conducted a phase I/II clinical trial using carbon ion radiotherapy (C-ion RT) for patients with operable and locally advanced pancreatic cancer. This was delivered preop- eratively in 8 fractions over 2 weeks, was well tolerated, and resulted in excellent local control and survival rates. C-ion RT for patients with locally advanced pancreatic cancer was also well tolerated, even when concomitantly administered with the highest dose of gemcitabine (1,000 mg/m2), and likewise resulted in a good survival rate. In this chapter, we discuss current treatment methods and the results of C-ion RT for pancreatic cancer at the National Institute of Radiological Sciences.",
author = "Shigeu Yamada and Kohtaro Terashima and Makoto Shinoto and Shigeo Yasuda and Miho Shiomi and Tetsuro Isozaki",
year = "2014",
month = "1",
day = "1",
doi = "10.1007/978-4-431-54457-9_26",
language = "English",
isbn = "9784431544562",
pages = "221--228",
booktitle = "Carbon-Ion Radiotherapy",
publisher = "Springer Japan",
address = "Japan",

}

TY - CHAP

T1 - Pancreatic cancer

AU - Yamada, Shigeu

AU - Terashima, Kohtaro

AU - Shinoto, Makoto

AU - Yasuda, Shigeo

AU - Shiomi, Miho

AU - Isozaki, Tetsuro

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Pancreatic cancer is the fifth leading cause of cancer death and is considered to be one of the most lethal cancers in Japan.Complete surgical resection is the only curative treatment. Even if curative resection is performed, the disease usually recurs, and 5-year survival rates are less than 20%. Chemotherapy or chemoradiotherapy is selected as a standard treatment for unresectable pancreatic cancer. However, since pancreatic cancer is often resistant to chemotherapy and radiotherapy, the local control and survival rates are very low. We conducted a phase I/II clinical trial using carbon ion radiotherapy (C-ion RT) for patients with operable and locally advanced pancreatic cancer. This was delivered preop- eratively in 8 fractions over 2 weeks, was well tolerated, and resulted in excellent local control and survival rates. C-ion RT for patients with locally advanced pancreatic cancer was also well tolerated, even when concomitantly administered with the highest dose of gemcitabine (1,000 mg/m2), and likewise resulted in a good survival rate. In this chapter, we discuss current treatment methods and the results of C-ion RT for pancreatic cancer at the National Institute of Radiological Sciences.

AB - Pancreatic cancer is the fifth leading cause of cancer death and is considered to be one of the most lethal cancers in Japan.Complete surgical resection is the only curative treatment. Even if curative resection is performed, the disease usually recurs, and 5-year survival rates are less than 20%. Chemotherapy or chemoradiotherapy is selected as a standard treatment for unresectable pancreatic cancer. However, since pancreatic cancer is often resistant to chemotherapy and radiotherapy, the local control and survival rates are very low. We conducted a phase I/II clinical trial using carbon ion radiotherapy (C-ion RT) for patients with operable and locally advanced pancreatic cancer. This was delivered preop- eratively in 8 fractions over 2 weeks, was well tolerated, and resulted in excellent local control and survival rates. C-ion RT for patients with locally advanced pancreatic cancer was also well tolerated, even when concomitantly administered with the highest dose of gemcitabine (1,000 mg/m2), and likewise resulted in a good survival rate. In this chapter, we discuss current treatment methods and the results of C-ion RT for pancreatic cancer at the National Institute of Radiological Sciences.

UR - http://www.scopus.com/inward/record.url?scp=84934268751&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84934268751&partnerID=8YFLogxK

U2 - 10.1007/978-4-431-54457-9_26

DO - 10.1007/978-4-431-54457-9_26

M3 - Chapter

AN - SCOPUS:84934268751

SN - 9784431544562

SP - 221

EP - 228

BT - Carbon-Ion Radiotherapy

PB - Springer Japan

ER -